Foundation for Promotion of Cardiology / стр. 9 из 30

Main news

Dear colleagues!

On August 28, 2026, the full texts of the new clinical guidelines were published on the official website of the European Society of Cardiology (ESC), dedicated to the issues of cardiovascular diseases and chronic kidney disease.

The provisions of these clinical recommendations were presented to the participants of a number of specially organized scientific sessions, and also served as a reason for active discussions.

Press release

Quadpill Strategy Gains Ground in Hypertension Several new antihypertensive agents are reshaping the therapeutic strategies for patients with uncontrolled or resistant hypertension. Agents such as baxdrostat, the first selective aldosterone synthase inhibitor, and aprocitentan, a dual endothelin receptor A and B antagonist, are paving the way for new drug combinations and a more personalized approach to blood pressure control.

Heart Risks Rise, Care Lags: New Stats Expose Harsh Truths Researchers compiled a national data report on the burden, quality of care, and mortality trends for major cardiovascular risk factors and conditions in the US.

Editorial Activity

cardiology book

New Atrial Fibrillation Guidelines Confront Underlying Illness Updated guidelines for the management of atrial fibrillation released by the European Society of Cardiology are revamping the approach to care for this complex, multifactorial disease.

In situ assembly of an injectable cardiac stimulator Without intervention, cardiac arrhythmias pose a risk of fatality. However, timely intervention can be challenging in environments where transporting a large, heavy defibrillator is impractical, or emergency surgery to implant cardiac stimulation devices is not feasible. Here, we introduce an injectable cardiac stimulator, a syringe loaded with a nanoparticle solution comprising a conductive polymer and a monomer that, upon injection, forms a conductive structure around the heart for cardiac stimulation.

Polycystic Ovary Syndrome: A Hidden Risk for Metabolic and Cardiovascular Diseases? Women with polycystic ovary syndrome (PCOS) face an increased risk for type 2 diabetes (T2D), metabolic dysfunction–associated steatotic liver disease (MASLD), and cardiovascular disease (CVD), although these risks vary depending on PCOS phenotype.

Can Electronic Decision Support Improve Acute Heart Failure Care in EDs? An electronic decision support tool may increase the prescription of guideline–directed medical therapy for patients with acute heart failure (AHF) in emergency departments (EDs), with no serious adverse events (SAEs) within 30 days among very low-risk patients who are discharged.

Evaluation of the World Health Organization-HEARTS hypertension control package in Bangladesh: a quasi-experimental trial The World Health Organization (WHO) promotes the HEARTS technical package for improving hypertension control worldwide, but its effectiveness has not been rigorously evaluated.

Common Eye Disorder May Be Linked to Maternal Hypertension Children whose mothers have a hypertensive disorder in pregnancy (HDP) may have an increased risk for strabismus, including exophoria and intermittent exotropia, new research shows. Preeclampsia and poorly controlled blood pressure may confer the greatest risk.

PET Imaging Finds Vulnerable Plaques That Cause MI A new technique that can locate vulnerable coronary plaques at risk of rupturing and causing a myocardial infarction (MI) could help identify patients at high cardiovascular risk who might need more intensive treatment.

New Insight Into CVD, Stroke Risk in Migraine Researchers are unraveling the complex relationship between cardiovascular (CV)- and stroke-related outcomes in migraine with, and without, aura.

Scientific news

Blood Pressure Variability Linked to Mortality in Patients With ANCA-Associated Vasculitis Among patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis undergoing maintenance therapy, greater visit-to-visit systolic blood pressure variability (SBPV) was independently associated with an increased risk for all-cause mortality.

Morphine Underused for End-of-Life Dyspnea in the Emergency Department Compared with Inpatient Care Among 250 patients presenting to the emergency department (ED) with dyspnea at the end of life, 15.2% received morphine in the ED, whereas 68% received it during subsequent inpatient care. Patients with lung cancer or a do-not-resuscitate order were more likely to receive morphine in the ED, but its use was not associated with reduced survival.

Present state and future of screening for atrial fibrillation: a state-of-the-art review Atrial fibrillation is the most common arrhythmia and is a leading cause of stroke and heart failure yet often remains undiagnosed. Screening has been proposed to identify asymptomatic AF and initiate preventive treatment, but evidence for reduction in hard clinical endpoints such as stroke and heart failure remains inconclusive.

Levosimendan versus dobutamine in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials Acute decompensated heart failure with reduced ejection fraction often requires inotropic support. While dobutamine is commonly used, its safety and efficacy remain debated. Levosimendan has emerged as a potential alternative, with distinct pharmacological properties.

Cardiovascular Benefits of Semaglutide in SELECT Trial Not Fully Explained by Weight Loss and Other Improvements In adults with obesity and established cardiovascular disease (CVD), semaglutide was associated with improvements in several risk factors. However, those changes only accounted for part of the reduced risk for major adverse cardiovascular events (MACE) noted in the SELECT trial.

Partners

Video resource

Channel "Cardioprogress"

CARDIOPROGRESS
Foundation for the advancement of cardiology